The health-care sector fell amid concerns a new wave of generic drugs could compete with newer biotechnology-based products. Shares of AbbVie and Johnson & Johnson fell after U.S. Food and Drug Administration documents hinted a cheaper competitor for the drug companies' blockbuster anti-inflammatory treatments from a Korean company could be headed to market soon. SciClone Pharmaceuticals rose after the maker of a Hepatitis B treatment said it was reviewing strategic alternatives, having settled a U.S. Securities and Exchange Commission investigation into its China operations.

-By Rob Curran, rob.curran@dowjones.com

(END) Dow Jones Newswires

February 05, 2016 16:26 ET (21:26 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Johnson and Johnson Charts.